Skip to main content
SpringerLink
Log in

Salvage ifosfamide-doxorubicin chemotherapy in patients with recurrent nasopharyngeal carcinoma pretreated with cisplatin-based chemotherapy

  • Original Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

This study evaluated the efficacy and toxicity of ifosfamide and doxorubicin chemotherapy regimen in Turkish patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) previously treated with platinum-based chemotherapy. Twenty-one patients with recurrent or metastatic NPC previously treated with platinum-based chemotherapy as adjuvant or palliative treatments who received ifosfamide 2500 mg/m2 d 1–3, mesna 2500 mg/m2 d 1–3, doxorubicin 60 mg/m2 d 1, repeated every 21 d was retrospectively analyzed. Patients received a median number of three cycles of ifosfamide-doxorubicin (range: 1–6). Seven patients (33.3%) achieved partial response and no patient achieved complete response. Six (28.5%) had stable disease, whereas three (18.75%) had progressive disease. The median time to progression was 7.0 mo. Ifosfamide-doxorubicin regimen is an effective salvage regimen in patients with recurrent and metastatic NPC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fandi A, Atum M, Azli N, Armand JP, Cvitkovic E. Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin Oncol 1994; 21:382–397.

    PubMed  CAS  Google Scholar 

  2. Vaughan TL, et al. Nasopharyngeal cancer in a low-risk population: defining risk factors by histological type. Cancer Epidemiol Biomarkers Prev 1996; 5:587–593.

    PubMed  CAS  Google Scholar 

  3. World Health Organization. International classification of tumors: histological typing of upper respiratory tract tumors. Geneva: World Health Organization, 1991.

    Google Scholar 

  4. Lee AW, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976–1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 1992; 23:261–270.

    PubMed  CAS  Google Scholar 

  5. Perez CA, et al. Carcinoma of the nasopharynx: factors affecting prognosis. Int J Radiat Oncol Biol Phys 1992; 23:271–280.

    PubMed  CAS  Google Scholar 

  6. Teo ML, Kwan WH, Lee WY, Leung SF, Johnson PJ. Prognosticators determining survival subsequent to distant metastases from nasopharyngeal carcinoma. Cancer 1996; 77:2423–2431.

    Article  PubMed  CAS  Google Scholar 

  7. Fandi A, et al. Long-term disease-free survivors in metastatic undifferentiated carcinoma of the nasopharyngeal type. J Clin Oncol 2000; 18:1324–1330.

    PubMed  CAS  Google Scholar 

  8. Chua DTT, Kwong DLW, Sham JST, Au GKH, Choy D. A phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapy. Eur J Cancer 2000; 36:736–741.

    Article  PubMed  CAS  Google Scholar 

  9. Foo KF, et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol 2002; 13:150–156.

    Article  PubMed  CAS  Google Scholar 

  10. Yeo W, et al. A phase II study combination of paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. Eur J Cancer 1998; 34:2027–2031.

    Article  PubMed  CAS  Google Scholar 

  11. Ma BB, Tannock IF, Pond GR, Edmonds MR, Siu LL. Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. Cancer 2002; 95:2516–2523.

    Article  PubMed  CAS  Google Scholar 

  12. Chua DT, Sham JS, Au GK. A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral Oncol 2003; 39:361–366.

    Article  PubMed  CAS  Google Scholar 

  13. Huang HQ, et al. Preliminary results of ifosfamide and doxorubicin regimen in treatment of patients with recurrent and metastatic nasopharyngeal carcinoma (Article in Chinese). Ai Zheng 2002; 21:409–411.

    PubMed  Google Scholar 

  14. McCarthy JS, et al. A phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma Oral Oncol 2002; 38:686–690.

    Article  PubMed  CAS  Google Scholar 

  15. Azli N, et al. Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer J Sci Am 1995; 1:222.

    PubMed  CAS  Google Scholar 

  16. Hasbini A, et al. Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type. Ann Oncol 1999; 10:421–425.

    Article  PubMed  CAS  Google Scholar 

  17. Taamma A, et al. Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer 1999; 86:1101–1108.

    Article  PubMed  CAS  Google Scholar 

  18. Siu LL, Czaykowski PM, Tannock IF, Phase I/II study of the CAPABLE regimen for patients with poorly differentiated carcinoma of the nasopharynx. J Clin Oncol 1998; 16:2514–2521.

    PubMed  CAS  Google Scholar 

  19. Onat H, et al. High-dose epirubicin and cisplatin in locally advanced undifferentiated nasopharyngeal carcinoma. Clin Oncol (R Coll Radiol) 2002; 14:449–454.

    CAS  Google Scholar 

  20. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey

    Kadri Altundag MD, Sercan Aksoy, Ibrahim Gullu, Ozden Altundag & Suayib Yalcin

  2. Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey

    Enis Ozyar, Mustafa Cengiz & Fadil Akyol

Authors
  1. Kadri Altundag MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sercan Aksoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ibrahim Gullu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ozden Altundag
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Enis Ozyar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Suayib Yalcin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mustafa Cengiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Fadil Akyol
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kadri Altundag MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Altundag, K., Aksoy, S., Gullu, I. et al. Salvage ifosfamide-doxorubicin chemotherapy in patients with recurrent nasopharyngeal carcinoma pretreated with cisplatin-based chemotherapy. Med Oncol 21, 211–215 (2004). https://doi.org/10.1385/MO:21:3:211

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1385/MO:21:3:211

Key Words

Search

Navigation